A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.

BACKGROUND: Options to treat elderly patients (=65 years old) newly diagnosed with acute myeloid leukemia (AML) include intensive and attenuated chemotherapy, hypomethylating agents with or without venetoclax, and supportive care. This multicenter, randomized, open-label, phase 3 trial was designed...

Descripción completa

Detalles Bibliográficos
Autores: Vives, Susana, Martinez-Cuadron, David, Bergua Burgues, Juan, Algarra, Lorenzo, Tormo, Mar, Martinez-Sanchez, Maria Pilar, Serrano, Josefina, Herrera, Pilar, Ramos, Fernando, Salamero, Olga, Lavilla, Esperanza, Lopez-Lorenzo, Jose L, Gil, Cristina, Vidriales, Belen, Falantes, Jose F, Serrano, Alfons, Labrador, Jorge, Sayas, Maria J, Foncillas, Maria A, Amador Barciela, Maria L, Olave, Maria Teresa, Colorado, Mercedes, Gascon, Adriana, Fernandez, Maria A, Simiele, Adriana, Perez-Encinas, Manuel M, Rodriguez-Veiga, Rebeca, Garcia, Olga, Martinez-Lopez, Joaquin, Barragan, Eva, Paiva, Bruno, Sanz, Miguel A, Montesinos, Pau, PETHEMA Group
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p15617
Acceso en línea:https://incliva.portalinvestigacion.com/publicaciones/15617
Access Level:acceso abierto
Palabra clave:acute myeloid leukemia
azacitidine
cytarabine
elderly patients
fludarabine
Descripción
Sumario:BACKGROUND: Options to treat elderly patients (=65 years old) newly diagnosed with acute myeloid leukemia (AML) include intensive and attenuated chemotherapy, hypomethylating agents with or without venetoclax, and supportive care. This multicenter, randomized, open-label, phase 3 trial was designed to assess the efficacy and safety of a fludarabine, cytarabine, and filgrastim (FLUGA) regimen in comparison with azacitidine (AZA). METHODS: Patients (n = 283) were randomized 1:1 to FLUGA (n = 141) or AZA (n = 142). Response was evaluated after cycles 1, 3, 6, and 9. Measurable residual disease (MRD) was assessed after cycle 9. When MRD was =0.01%, patients continued with the treatment until relapse or progressive disease. Patients with MRD < 0.01% suspended treatment to enter the follow-up phase. RESULTS: The complete remission (CR) rate after 3 cycles was significantly better in the FLUGA arm (18% vs 9%; P = .04), but the CR/CR with incomplete recovery rate at 9 months was similar (33% vs 29%; P = .41). There were no significant differences between arms in early mortality at 30 or 60 days. Hematologic toxicities were more frequent with FLUGA, especially during induction. The 1-year overall survival (OS) rate and the median OS were superior with AZA versus FLUGA: 47% versus 27% and 9.8 months (95% confidence interval [CI], 5.6-14 months) versus 4.1 months (95% CI, 2.7-5.5 months; P = .005), respectively. The median event-free survival was 4.9 months (95% CI, 2.8-7 months) with AZA and 3 months (95% CI, 2.5-3.5 months) with FLUGA (P = .001). CONCLUSIONS: FLUGA achieved more remissions after 3 cycles, but the 1-year OS rate was superior with AZA. However, long-term outcomes were disappointing in both arms (3-year OS rate, 10% vs 5%). This study supports the use of an AZA backbone for future combinations in elderly patients with AML.

Similares en LA Referencia